VivoSeq
Neurology

Peripheral Neuropathy Due to Chemotherapy

0

Pipeline Programs↗

1

Active Trials↗

0

Companies Involved↗

Peripheral Neuropathy Due to Chemotherapy is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

2

clinical trials

Recruiting1 · 50%
Completed1 · 50%

Clinical Trials

Trial Activity

Exploring the Benefit of Topical Capsaicin in Treating Pain From Chemo-induced Peripheral Neuropathy: a Longitudinal Single Center Pilot Study
Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT06744816·20 enrolled
Patient-identified Values as Outcome Targets (PIVOT) Feasibility Pilot Trial
Completed·MM.D. Anderson Cancer Center·Preclinical·NCT06736600·33 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)